NCT00873730View on ClinicalTrials.gov

Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain

PHASE4CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Ankylosing Spondylitis
Interventions
DRUG

etanercept

Etanercept 50 mg twice a week (BIW) for 12 weeks

DRUG

etanercept/placebo

Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00873730 - Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain | Biotech Hunter | Biotech Hunter